A Phase IIB , Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo/Active Controlled Study to Evaluate the Efficacy and Safety of BMS-945429 Subcutaneous Injection With or Without Methotrexate in Subjects with Moderate to Severe Rheumatoid Arthritis with Inadequate Response to Methotrexate

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F14%3A%230000736" target="_blank" >RIV/00064190:_____/14:#0000736 - isvavai.cz</a>

Result on the web

—

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

A Phase IIB , Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo/Active Controlled Study to Evaluate the Efficacy and Safety of BMS-945429 Subcutaneous Injection With or Without Methotrexate in Subjects with Moderate to Severe Rheumatoid Arthritis with Inadequate Response to Methotrexate

Original language description

The purpose of this study is to determine the effective dose of BMS-945429 in subjects with inadequate response to methotrexate in the treatment of moderate to severe Rheumatoid Arthritis Secondary objectives of the trial ACR 50 ACR 70 Disease Activity Score-c Reactive Protein (DAS-CRP) Clinical Disease Activity Index Physical Function Magnetic Resonance Imaging (MRI) X-Ray Health Related Quality of Life outcomes Safety (number of adverse events)

Czech name

—

Czech description

—

Type

V_utaj - Research report containing classified information

CEP classification

FP - Other medical fields

OECD FORD branch

—

Project

—

Continuities

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Publication year

2014

Confidentiality

U - Předmět řešení projektu je utajovanou skutečností podle zvláštních právních předpisů nebo je skutečností, jejíž zveřejnění by mohlo ohrozit činnost zpravodajské služby. Údaje o projektu jsou upraveny tak, aby byly zveřejnitelné

Number of pages

2

Place of publication

Praha

Publisher/client name

Bristol-Myers Squibb, spol. s r.o.

Version

—